California State Teachers Retirement System Grows Position in ICU Medical, Inc. $ICUI

Key Points

• California State Teachers Retirement System increased its ICU Medical stake by 25.2% in the first quarter, bringing its holdings to 27,512 shares valued at approximately $3.55 million. Institutional investors and hedge funds collectively own 96.1% of the company.
• ICU Medical reported a strong second quarter, with adjusted EPS of $2.37 versus the $1.91 analyst consensus and revenue of $547.9 million versus expectations of $533.4 million. The company set fiscal 2026 EPS guidance at $8.60–$9.00.
• Analysts largely remain bullish, with several raising price targets to as high as $200 and MarketBeat assigning the stock a “Moderate Buy” consensus rating. However, ICU Medical’s elevated P/E ratio of 156.41 leaves the shares dependent on continued earnings growth.

California State Teachers Retirement System grew its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 25.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,512 shares of the medical instruments supplier's stock after purchasing an additional 5,536 shares during the period. California State Teachers Retirement System owned approximately 0.11% of ICU Medical worth $3,553,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Hilton Head Capital Partners LLC purchased a new stake in ICU Medical during the fourth quarter worth about $32,000. Covestor Ltd grew its position in ICU Medical by 22.1% during the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock worth $99,000 after buying an additional 126 shares during the period. Strs Ohio increased its holdings in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after buying an additional 300 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in ICU Medical by 21.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier's stock valued at $117,000 after buying an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in ICU Medical in the fourth quarter valued at about $120,000. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm's stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the sale, the director directly owned 7,960 shares of the company's stock, valued at $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company's stock.

ICU Medical News Summary

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

ICU Medical Trading Up 10.9%

ICU Medical stock opened at $184.56 on Friday. The stock has a market cap of $4.61 billion, a PE ratio of 156.41, a P/E/G ratio of 2.58 and a beta of 0.74. The stock has a 50-day moving average price of $151.64 and a 200 day moving average price of $141.02. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $192.85. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. During the same period in the prior year, the firm earned $2.10 EPS. The firm's quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Sanford C. Bernstein lowered ICU Medical to a "market perform" rating in a research note on Monday, June 15th. Zacks Research downgraded ICU Medical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an "overweight" rating in a report on Tuesday, July 21st. Raymond James Financial reiterated a "strong-buy" rating and set a $200.00 target price on shares of ICU Medical in a research report on Friday. Finally, BTIG Research upped their target price on ICU Medical from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $192.80.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source